TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma

Table 1 Association between transducin (β)-like 1 X-linked receptor 1 expression and the clinicopathological parameters of pancreatic ductal adenocarcinoma cells

Parameter	Category	Case number	TBL1XR1 expression
			Number of positive cases, n (%)	χ2	P value
Age (yrs)	< 60	40	27 (67.5)	0.214	0.652
	≥ 60	50	36 (72.0)
Sex	Male	59	41 (69.5)	0.021	1.000
	Female	31	22 (71.0)
Histopathological subtypes	High	3	2 (66.7)	0.146	0.929
	Middle	51	35 (68.6)
	Low	36	26 (72.2)
TNM stage	1-II	12	4 (33.3)	8.864	0.006b
	III-IV	78	59 (75.6)
Tumor size	< 3 cm	60	42 (66.7)	0.952	0.465
	≥ 3 cm	30	23 (76.7)
Tumor location	Head	37	30 (81.1)	3.674	0.065
	Body/tail	53	33 (62.3)
Lymph node metastasis	Negative	61	44 (72.1)	0.409	0.624
	Positive	29	19 (65.5)

^bP < 0.01. TBL1XR1: Transducin (β)-like 1 X-linked receptor 1; PDAC: Pancreatic ductal adenocarcinoma; TNM: Tumor-node-metastasis.